<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00666848</url>
  </required_header>
  <id_info>
    <org_study_id>070977</org_study_id>
    <nct_id>NCT00666848</nct_id>
  </id_info>
  <brief_title>Effect of Sitagliptin and an ACE Inhibitor on Blood Pressure in Metabolic Syndrome</brief_title>
  <official_title>Effect of Sitagliptin on the Blood Pressure Response to ACE Inhibition in the Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will measure the effect of the anti-diabetic agent sitagliptin on blood pressure
      in individuals with the metabolic syndrome. We will also measure the effect of sitagliptin on
      blood pressure in people already taking a blood pressure medication called an ACE inhibitor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prevalence of metabolic syndrome and Type 2 diabetes mellitus (T2DM) has reached epidemic
      proportions in developed countries and is closely associated with hypertension. As new oral
      hypoglycemic agents become available for clinical use, practitioners wishing to treat both
      hyperglycemia and hypertension will use varieties of combinations of medications. In this
      setting, understanding interactions and additive effects of these medications becomes
      essential. Sitagliptin, a selective dipeptidyl peptidase-IV (DPP-4) inhibitor, improves
      glycemic control in patients with T2DM by decreasing the degradation of the incretin
      hormones. The incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent
      insulinotropic peptide (GIP) augment nutrient mediated insulin release. To date there have
      been two reports of a blood pressure lowering effect of the DPP-4 inhibitor vildagliptin, but
      no mechanism for this effect has been proposed.

      Specific Aim 1: To test the hypothesis that the DPP-4 inhibitor sitagliptin lowers blood
      pressure compared to placebo therapy in subjects with the metabolic syndrome.

      Specific Aim 2: To test the hypothesis that the DPP-4 inhibitor sitagliptin potentiates the
      blood pressure response to acute ACE-inhibition.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in MAP During Placebo</measure>
    <time_frame>just prior to drug administration and 8 hours after drug administration</time_frame>
    <description>The change in mean arterial pressure (MAP) in response to placebo or enalapril after pretreatment with 5 days of placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in MAP During Sitagliptin</measure>
    <time_frame>just prior to drug administration and 8 hours following treatment</time_frame>
    <description>Mean change in mean arterial pressure in response to placebo or enalapril in the presence of 5 days of sitagliptin 100mg/day</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>2 (enalapril 5mg)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects received Enalapril 5mg on study day and a placebo pill for 5 days prior or subjects received enalapril 5mg on study day and sitagliptin 100mg/day for 5 days prior .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1 (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects received a placebo pill on study day and received a placebo pill for 5 days prior or subjects received a Placebo pill on study day and sitagliptin 100mg for 5 days prior.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 (enalapril 10mg)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects received Enalapril 10mg on study day and a placebo pill for 5 days prior, or subjects received Enalapril 10mg on study day and sitagliptin 100mg for 5 days prior.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Enalapril 0mg after 5 days of placebo versus after 5 days sitagliptin 100mg/d</description>
    <arm_group_label>1 (placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enalapril 5mg</intervention_name>
    <description>Enalapril 5 mg after 5 days placebo versus after 5 days sitagliptin 100mg/d</description>
    <arm_group_label>2 (enalapril 5mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enalapril 10mg</intervention_name>
    <description>Enalapril 10mg after 5 days placebo versus after 5 days sitagliptin 100 mg/d</description>
    <arm_group_label>3 (enalapril 10mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>Sitagliptin 100mg/day for 5 days crossed over to placebo daily for 5 days prior to arms.</description>
    <arm_group_label>2 (enalapril 5mg)</arm_group_label>
    <arm_group_label>1 (placebo)</arm_group_label>
    <arm_group_label>3 (enalapril 10mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ambulatory subjects, 18 to 70 years of age, inclusive

          -  For female subjects, the following criteria must be met:

               -  Postmenopausal for at least 1 year, or

               -  Status-post surgical sterilization, or

               -  If of childbearing potential, utilization of barrier contraceptive and
                  willingness to undergo beta-hcg testing prior to drug treatment and on every
                  study day

          -  Metabolic syndrome as defined by 3 or more of the following:

               -  Fasting plasma glucose of at least 100 mg/dL (5.6 mmol/L)

               -  Serum triglycerides of at least 150 mg/dL (1.7 mmol/L)

               -  Serum HDL less than or equal to 40 mg/dL in men or less than 50 mg/dL in women or
                  on cholesterol-lowering medications

               -  Blood pressure of at least 130/85 mmHg or on blood-pressure lowering medications

               -  Waist girth of more than 102 cm in med or 88 cm in women

          -  Statin therapy for hypercholesterolemia must be a steady dose for 6 months prior to
             study day

        Exclusion Criteria:

          -  Diabetes type 1 or type 2, as defined by a fasting glucose of 126 mg/dL or greater or
             the use of anti-diabetic medication

          -  History of reported or recorded hypoglycemia (plasma glucose less than 70 mg/dL)

          -  Use of hormone replacement therapy

          -  In hypertensive patients, a seated systolic blood pressure greater than 179 mmHg or a
             seated diastolic blood pressure greater than 110 mmHg

          -  Pregnancy

          -  Breast-feeding

          -  Cardiovascular disease such as myocardial infarction within 6 months prior to
             enrollment, presence of angina pectoris, significant arrhythmia, congestive heart
             failure (LV hypertrophy acceptable), deep vein thrombosis, pulmonary embolism, second
             or third degree heart block, mitral valve stenosis, aortic stenosis or hypertrophic
             cardiomyopathy

          -  Treatment with anticoagulants

          -  History of serious neurological disease such as cerebral hemorrhage, stroke, or
             transient ischemic attack

          -  History or presence of immunological or hematological disorders

          -  Diagnosis of current asthma

          -  History of angioedema associated with use of ACE-I

          -  Clinically significant gastrointestinal impairment that could interfere with drug
             absorption

          -  Impaired hepatic function (aspartate amino transaminase [AST] and/or alanine amino
             transferase [ALT] &gt; 2.0 x upper limit of normal range)

          -  Impaired renal function (serum creatinine &gt; 1.5 mg/dl)

          -  Hematocrit &lt;35%

          -  Any underlying or acute disease requiring regular medication which could possibly pose
             a threat to the subject or make implementation of the protocol or interpretation of
             the study results difficult

          -  Treatment with chronic systemic glucocorticoid therapy (more than 7 consecutive days
             in 1 month)

          -  Treatment with lithium salts

          -  History of alcohol or drug abuse

          -  Treatment with any investigational drug in the 1 month preceding the study

          -  Mental conditions rendering the subject unable to understand the nature, scope and
             possible consequences of the study

          -  Inability to comply with the protocol, e.g. uncooperative attitude, inability to
             return for follow-up visits, and unlikelihood of completing the study

          -  Oral contraceptives
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy J Brown, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Marney A, Kunchakarra S, Byrne L, Brown NJ. Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension. 2010 Oct;56(4):728-33. doi: 10.1161/HYPERTENSIONAHA.110.156554. Epub 2010 Aug 2.</citation>
    <PMID>20679179</PMID>
  </results_reference>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2008</study_first_submitted>
  <study_first_submitted_qc>April 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2008</study_first_posted>
  <results_first_submitted>September 4, 2011</results_first_submitted>
  <results_first_submitted_qc>April 12, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 11, 2012</results_first_posted>
  <last_update_submitted>April 12, 2012</last_update_submitted>
  <last_update_submitted_qc>April 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Nancy J. Brown</investigator_full_name>
    <investigator_title>Robert H. Williams Professor of Medicine and Pharmacology</investigator_title>
  </responsible_party>
  <keyword>Metabolic syndrome</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Sitagliptin</keyword>
  <keyword>Enalapril</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Enalapril</mesh_term>
    <mesh_term>Enalaprilat</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Subjects received a placebo pill for 5 days prior then arm 1,2,or3 and crossed over to sitagliptin 100mg/day for 5 days prior to arm 1,2,or3. This is a parallel cross over study. 43 subjects were consented. 15 did not meet inclusion criteria. 3 withdrew before randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>2 (Enalapril 5mg)</title>
          <description>Subjects received Enalapril 5mg on study day and a placebo pill for 5 days prior or subjects received enalapril 5mg on study day and sitagliptin 100mg/day for 5 days prior .</description>
        </group>
        <group group_id="P2">
          <title>1 (Placebo)</title>
          <description>Subjects received a placebo pill on study day and received a placebo pill for 5 days prior or subjects received a Placebo pill on study day and sitagliptin 100mg for 5 days prior.</description>
        </group>
        <group group_id="P3">
          <title>3 (Enalapril 10mg)</title>
          <description>Subjects received Enalapril 10mg on study day and a placebo pill for 5 days prior, or subjects received Enalapril 10mg on study day and sitagliptin 100mg for 5 days prior.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8">15 didn't meet inclusion criteria. 3 withdrew before randomized. 1 withdrawn before randomized.</participants>
                <participants group_id="P2" count="9">15 didn't meet inclusion criteria. 3 withdrew before randomized. 1 withdrawn before randomized.</participants>
                <participants group_id="P3" count="7">15 didn't meet inclusion criteria. 3 withdrew before randomized. 1 withdrawn before randomized.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8">finished Aim 2</participants>
                <participants group_id="P2" count="9">finished Aim 1</participants>
                <participants group_id="P3" count="7">finished Aim 3</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>2 (Enalapril 5mg)</title>
          <description>Subjects received Enalapril 5mg on study day and a placebo pill for 5 days prior or subjects received enalapril 5mg on study day and sitagliptin 100mg/day for 5 days prior .</description>
        </group>
        <group group_id="B2">
          <title>1 (Placebo)</title>
          <description>Subjects received a placebo pill on study day and received a placebo pill for 5 days prior or subjects received a Placebo pill on study day and sitagliptin 100mg for 5 days prior.</description>
        </group>
        <group group_id="B3">
          <title>3 (Enalapril 10mg)</title>
          <description>Subjects received Enalapril 10mg on study day and a placebo pill for 5 days prior, or subjects received Enalapril 10mg on study day and sitagliptin 100mg for 5 days prior.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42" spread="9.8"/>
                    <measurement group_id="B2" value="44" spread="13.9"/>
                    <measurement group_id="B3" value="41" spread="9.1"/>
                    <measurement group_id="B4" value="43" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in MAP During Placebo</title>
        <description>The change in mean arterial pressure (MAP) in response to placebo or enalapril after pretreatment with 5 days of placebo</description>
        <time_frame>just prior to drug administration and 8 hours after drug administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>2 (Enalapril 5mg)</title>
            <description>Subjects received Enalapril 5mg on study day and a placebo pill for 5 days prior or subjects received enalapril 5mg on study day and sitagliptin 100mg/day for 5 days prior .</description>
          </group>
          <group group_id="O2">
            <title>1 (Placebo)</title>
            <description>Subjects received a placebo pill on study day and received a placebo pill for 5 days prior or subjects received a Placebo pill on study day and sitagliptin 100mg for 5 days prior.</description>
          </group>
          <group group_id="O3">
            <title>3 (Enalapril 10mg)</title>
            <description>Subjects received Enalapril 10mg on study day and a placebo pill for 5 days prior, or subjects received Enalapril 10mg on study day and sitagliptin 100mg for 5 days prior.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in MAP During Placebo</title>
          <description>The change in mean arterial pressure (MAP) in response to placebo or enalapril after pretreatment with 5 days of placebo</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="2.5"/>
                    <measurement group_id="O2" value="2.7" spread="2.1"/>
                    <measurement group_id="O3" value="-7.9" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in MAP During Sitagliptin</title>
        <description>Mean change in mean arterial pressure in response to placebo or enalapril in the presence of 5 days of sitagliptin 100mg/day</description>
        <time_frame>just prior to drug administration and 8 hours following treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>2 (Enalapril 5mg)</title>
            <description>Subjects received Enalapril 5mg on study day and a placebo pill for 5 days prior or subjects received enalapril 5mg on study day and sitagliptin 100mg/day for 5 days prior .</description>
          </group>
          <group group_id="O2">
            <title>1 (Placebo)</title>
            <description>Subjects received a placebo pill on study day and received a placebo pill for 5 days prior or subjects received a Placebo pill on study day and sitagliptin 100mg for 5 days prior.</description>
          </group>
          <group group_id="O3">
            <title>3 (Enalapril 10mg)</title>
            <description>Subjects received Enalapril 10mg on study day and a placebo pill for 5 days prior, or subjects received Enalapril 10mg on study day and sitagliptin 100mg for 5 days prior.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in MAP During Sitagliptin</title>
          <description>Mean change in mean arterial pressure in response to placebo or enalapril in the presence of 5 days of sitagliptin 100mg/day</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.7" spread="2.0"/>
                    <measurement group_id="O2" value="-2.3" spread="2.0"/>
                    <measurement group_id="O3" value="-0.9" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>2 (Enalapril 5mg)</title>
          <description>Subjects received Enalapril 5mg on study day and a placebo pill for 5 days prior or subjects received enalapril 5mg on study day and sitagliptin 100mg/day for 5 days prior .</description>
        </group>
        <group group_id="E2">
          <title>1 (Placebo)</title>
          <description>Subjects received a placebo pill on study day and received a placebo pill for 5 days prior or subjects received a Placebo pill on study day and sitagliptin 100mg for 5 days prior.</description>
        </group>
        <group group_id="E3">
          <title>3 (Enalapril 10mg)</title>
          <description>Subjects received Enalapril 10mg on study day and a placebo pill for 5 days prior, or subjects received Enalapril 10mg on study day and sitagliptin 100mg for 5 days prior.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nancy J. Brown, M.D.</name_or_title>
      <organization>Vanderbilt University School of Medicine</organization>
      <phone>615-343-8701</phone>
      <email>nancy.j.brown@vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

